Synairgen no wheeze as asthma drug trial boosts shares

Southampton based research firm, Synairgen, has rocketed in morning trading after announcing results for a treatment which could protect asthmatics from respiratory virus infections.

The drug, called SNG001, stops infections like the common cold spreading to patients' lungs, which is often the cause of hospital admissions for asthma sufferers.

The study investigated SNG001 in a population of 134 adult asthma patients, representing 'mild-moderate' through to 'severe' asthmatics, who caught a cold.

MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Patients with 'difficult to treat' asthma, being approximately half of the patients in the trial, benefitted significantly from SNG001 treatment. This category of patient is estimated to represent between 10% and 20% of all adult asthma sufferers.

Professor Stephen Holgate, the founder of Synairgen, said: "This is the first clinical study which appears to demonstrate that, by boosting the antiviral defences of the lungs of asthmatics...we can...prevent worsening of asthma symptoms in a high risk group of patients."

He'll certainly have been breathing easily after looking at his firm's share price this morning, the stock had gained 27.6% by 10:59.

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.